84 related articles for article (PubMed ID: 16777971)
1. Peroxisomal proliferator-activated receptor-gamma agonists induce partial reversion of epithelial-mesenchymal transition in anaplastic thyroid cancer cells.
Aiello A; Pandini G; Frasca F; Conte E; Murabito A; Sacco A; Genua M; Vigneri R; Belfiore A
Endocrinology; 2006 Sep; 147(9):4463-75. PubMed ID: 16777971
[TBL] [Abstract][Full Text] [Related]
2. Evaluation of the Therapeutic Effects of Harmine on Anaplastic Thyroid Cancer Cells.
Baldini E; Cardarelli S; Campese AF; Lori E; Fallahi P; Virili C; Forte F; Pironi D; Di Matteo FM; Palumbo P; Costanzo ML; D'Andrea V; Centanni M; Sorrenti S; Antonelli A; Ulisse S
Int J Mol Sci; 2024 Jan; 25(2):. PubMed ID: 38256193
[TBL] [Abstract][Full Text] [Related]
3. Design, Synthesis, and Biological Evaluation of Novel Quercetin Derivatives as PPAR-γ Partial Agonists by Modulating Epithelial-Mesenchymal Transition in Lung Cancer Metastasis.
Ballav S; Bhosale M; Lokhande KB; Paul MK; Padhye S; Swamy KV; Ranjan A; Basu S
Adv Biol (Weinh); 2023 Oct; 7(10):e2300036. PubMed ID: 37017501
[TBL] [Abstract][Full Text] [Related]
4. Abemaciclib-induced epithelial-mesenchymal transition mediated by cyclin-dependent kinase 4/6 independent of cell cycle arrest pathway.
Yoshimori T; Kawami M; Kumagai Y; Futatsugi S; Yumoto R; Uchida Y; Takano M
Int J Biochem Cell Biol; 2024 May; 172():106601. PubMed ID: 38821314
[TBL] [Abstract][Full Text] [Related]
5. PPAR-γ agonists and their effects on IGF-I receptor signaling: Implications for cancer.
Belfiore A; Genua M; Malaguarnera R
PPAR Res; 2009; 2009():830501. PubMed ID: 19609453
[TBL] [Abstract][Full Text] [Related]
6. Lysicamine Reduces Protein Kinase B (AKT) Activation and Promotes Necrosis in Anaplastic Thyroid Cancer.
Rodrigues MT; Michelli APP; Caso GF; de Oliveira PR; Rodrigues-Junior DM; Morale MG; Machado Júnior J; Bortoluci KR; Tamura RE; da Silva TRC; Raminelli C; Chau E; Godin B; Calil-Silveira J; Rubio IGS
Pharmaceuticals (Basel); 2023 Dec; 16(12):. PubMed ID: 38139812
[TBL] [Abstract][Full Text] [Related]
7. Anaplastic Thyroid Cancer Cells Upregulate Mitochondrial One-Carbon Metabolism To Meet Purine Demand, Eliciting A Critical Targetable Vulnerability.
Sugarman AJ; Huynh LD; Shabro A; Di Cristofano A
bioRxiv; 2023 Apr; ():. PubMed ID: 37162981
[TBL] [Abstract][Full Text] [Related]
8. Novel Insights in the Genomics of Anaplastic Thyroid Carcinoma: A Role for Cyclin-Dependent Kinase Inhibition?
Stenman A; Juhlin CC
Cancers (Basel); 2023 Sep; 15(18):. PubMed ID: 37760590
[TBL] [Abstract][Full Text] [Related]
9. Drug repositioning in thyroid cancer treatment: the intriguing case of anti-diabetic drugs.
Greco A; Coperchini F; Croce L; Magri F; Teliti M; Rotondi M
Front Pharmacol; 2023; 14():1303844. PubMed ID: 38146457
[TBL] [Abstract][Full Text] [Related]
10. Impaired Glucose Metabolism, Anti-Diabetes Medications, and Risk of Thyroid Cancer.
Kushchayeva Y; Kushchayev S; Jensen K; Brown RJ
Cancers (Basel); 2022 Jan; 14(3):. PubMed ID: 35158824
[TBL] [Abstract][Full Text] [Related]
11. Lobeglitazone, A Peroxisome Proliferator-Activated Receptor-Gamma Agonist, Inhibits Papillary Thyroid Cancer Cell Migration and Invasion by Suppressing p38 MAPK Signaling Pathway.
Jin JQ; Han JS; Ha J; Baek HS; Lim DJ
Endocrinol Metab (Seoul); 2021 Oct; 36(5):1095-1110. PubMed ID: 34645125
[TBL] [Abstract][Full Text] [Related]
12. Tumor reversion: a dream or a reality.
Tripathi A; Kashyap A; Tripathi G; Yadav J; Bibban R; Aggarwal N; Thakur K; Chhokar A; Jadli M; Sah AK; Verma Y; Zayed H; Husain A; Bharti AC; Kashyap MK
Biomark Res; 2021 May; 9(1):31. PubMed ID: 33958005
[TBL] [Abstract][Full Text] [Related]
13. Recent advances in the management of anaplastic thyroid cancer.
De Leo S; Trevisan M; Fugazzola L
Thyroid Res; 2020 Nov; 13(1):17. PubMed ID: 33292371
[TBL] [Abstract][Full Text] [Related]
14. Micronutrients and Breast Cancer Progression: A Systematic Review.
Cuenca-Micó O; Aceves C
Nutrients; 2020 Nov; 12(12):. PubMed ID: 33255538
[TBL] [Abstract][Full Text] [Related]
15. Combination of peroxisome proliferator-activated receptor gamma and retinoid X receptor agonists induces sodium/iodide symporter expression and inhibits cell growth of human thyroid cancer cells.
Chen JY; Wang JJ; Lee HC; Chi CW; Lee CH; Hsu YC
J Chin Med Assoc; 2020 Oct; 83(10):923-930. PubMed ID: 33009242
[TBL] [Abstract][Full Text] [Related]
16. Molecular mechanisms of long non-coding RNAs in anaplastic thyroid cancer: a systematic review.
Samimi H; Sajjadi-Jazi SM; Seifirad S; Atlasi R; Mahmoodzadeh H; Faghihi MA; Haghpanah V
Cancer Cell Int; 2020; 20():352. PubMed ID: 32760219
[TBL] [Abstract][Full Text] [Related]
17. Novel treatments for anaplastic thyroid carcinoma.
Ferrari SM; Elia G; Ragusa F; Ruffilli I; La Motta C; Paparo SR; Patrizio A; Vita R; Benvenga S; Materazzi G; Fallahi P; Antonelli A
Gland Surg; 2020 Jan; 9(Suppl 1):S28-S42. PubMed ID: 32055496
[TBL] [Abstract][Full Text] [Related]
18. The paramount role of cytokines and chemokines in papillary thyroid cancer: a review and experimental results.
Fallahi P; Ferrari SM; Piaggi S; Luconi M; Cantini G; Gelmini S; Elia G; Ruffilli I; Antonelli A
Immunol Res; 2018 Dec; 66(6):710-722. PubMed ID: 30617967
[TBL] [Abstract][Full Text] [Related]
19. 15-Deoxy-Δ
Wu YC; Jhao YT; Cheng YC; Chen Y
Oncol Lett; 2017 Apr; 13(4):2569-2576. PubMed ID: 28454435
[TBL] [Abstract][Full Text] [Related]
20. PPAR-γ Agonists As Antineoplastic Agents in Cancers with Dysregulated IGF Axis.
Vella V; Nicolosi ML; Giuliano S; Bellomo M; Belfiore A; Malaguarnera R
Front Endocrinol (Lausanne); 2017; 8():31. PubMed ID: 28275367
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
